Cost-effectiveness of subcutaneous anti−tumour necrosis factor therapy in patients with psoriatic arthritis

Trial Profile

Cost-effectiveness of subcutaneous anti−tumour necrosis factor therapy in patients with psoriatic arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2012

At a glance

  • Drugs Adalimumab; Etanercept; Golimumab; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2012 New trial record
    • 20 Mar 2012 Results presented at the 70th Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top